# Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL

> **NCT04659434** · PHASE2 · UNKNOWN · sponsor: **Qian Wenbin** · enrollment: 51 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Relapsed Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT04659434
- **Lead sponsor:** Qian Wenbin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-10
- **Primary completion:** 2022-12-10
- **Final completion:** 2025-12-10
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2020-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04659434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04659434, "Sintilimab Plus R-GemOx as Second-line Salvage Therapy in Patients With R/R DLBCL". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04659434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*